Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a prospective, randomised and controlled pilot study
Completed
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn?s Disease (CD), Ulcerative Colitis (UC)Digestive SystemNoninfective enteritis and colitis
- Registration Number
- ISRCTN92101486
- Lead Sponsor
- Solvay Pharmaceuticals GmbH (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
To be included in the trial, patients had to present IBD. The majority of patients enrolled in this study were hospitalised because of symptoms of active disease and in most of them the clinical activity was confirmed by elevated Clinical Activity Index (CAI) scores in UC or elevated Crohn?s Disease Activity Index (CDAI) scores. The diagnosis of IBD was confirmed by classical clinical and endoscopic means according to the German and Austrian guidelines for UC and CD.
Exclusion Criteria
1. Surgery during study period
2. Other diseases than IBD
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method